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Background: Mesenchymal stromal cells (MSCs) represent heterogeneous cell population suitable for cell therapies
in regenerative medicine. MSCs can also substantially affect tumor biology due to their ability to be recruited to the
tumor stroma and interact with malignant cells via direct contacts and paracrine signaling. The aim of our study
was to characterize molecular changes dictated by adipose tissue-derived mesenchymal stromal cells (AT-MSCs)
and the effects on drug responses in human breast cancer cells SKBR3.
Methods: The tumor cells were either directly cocultured with AT-MSCs or exposed to MSCs-conditioned medium
(MSC-CM). Changes in cell biology were evaluated by kinetic live cell imaging, fluorescent microscopy, scratch
wound assay, expression analysis, cytokine secretion profiling, ATP-based viability and apoptosis assays. The effi-
ciency of cytotoxic treatment in the presence of AT-MSCs or MSCs-CM was analyzed.
Results: The AT-MSCs altered tumor cell morphology, induced epithelial-to-mesenchymal transition, increased
mammosphere formation, cell confluence and migration of SKBR3. These features were attributed to molecular
changes induced by MSCs-secreted cytokines and chemokines in breast cancer cells. AT-MSCs significantly inhibited
the proliferation of SKBR3 cells in direct cocultures which was shown to be dependent on the SDF-1α/CXCR4 signal-
ing axis. MSC-CM-exposed SKBR3 or SKBR3 in direct coculture with AT-MSCs exhibited increased chemosensitivity
and induction of apoptosis in response to doxorubicin and 5-fluorouracil.
Conclusions: Our work further highlights the multi-level nature of tumor-stromal cell interplay and demonstrates
the capability of AT-MSCs and MSC-secreted factors to alter the anti-tumor drug responses.
Keywords: Adipose tissue-derived mesenchymal stromal cells, Human breast cancer, Chemoresistance, Proliferation,
Epithelial-to-mesenchymal transition, Cytokine profileBackground
Breast cancer still remains one of the most common
malignancies in women with multiple risk factors [1].
Any solid tumor derived from breast epithelial tissue is
supported by tumor stroma – a non-malignant tumor
compartment composed from multiple cell types and
non-cellular components. The tumor microenvironment
creates a complex signaling network which substantially
affects tumor biology and therapeutic responsiveness
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reproduction in any medium, provided the orconstituent in the breast and also a rich source of mesen-
chymal stromal cells (MSCs) which contribute to mam-
mary carcinogenesis [4]. As a fat grafting procedure is
frequently used in breast reconstruction, breast contour
deformity correction or even in breast augmentation, it
also carries potential oncological risk of de novo breast
cancer and/or its recurrence [5,6].
The MSCs derived from the adipose tissue (AT-MSCs)
share a number of key characteristics with the bone
marrow-derived MSCs (BM-MSCs) [7-9]. MSCs from
both sources were demonstrated to integrate into
tumor-associated stroma and exhibit multiple regulatory
functions in the tumor microenvironment [10-12]. Ex-
perimental data revealed the capability of BM-MSCs toal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and even create a cancer stem cell niche [16] when ex-
posed to tumor-conditioned medium. The interaction of
BM-MSCs and breast cancer cells was also shown to
promote metastatic spread as a result of bidirectional
paracrine signaling [17]. Although the effect on prolife-
ration of the tumor cells was not stimulatory in general,
MSCs were shown to promote tumor cell migration, an
epithelial-to-mesenchymal transition (EMT), mediate
release from the hormone-dependence, and increase
chemoresistance in breast cancer cells [18-23]. MSCs-
secreted factors increased mammosphere formation and
the exosomes from MSCs were sufficient to support the
growth of tumor xenografts [24-26]. Taken together
these data suggest that BM-MSCs promote breast cancer
growth and/or metastatic spread. However, a suppres-
sion of the tumor growth by MSCs was reported for the
tumor types other then breast; and the role of MSCs in
tumor growth remains a matter of further investigations
[12,27-29]. Better understanding of the underlying
mechanisms might lead to the therapeutic intervention
with the aim to increase an antitumor response [30,31].
MSCs themselves can be specifically engineered for the
increased tumor-targeting and efficiency of the anti-
tumor treatment [32]. The introduction of specific trans-
gene(s) into the AT-MSCs sensitized the breast cancer
cells MDA-MB-231 to the chemotherapeutic drug 5FU
for in vitro [33].
We have previously characterized the effect of AT-
MSCs on the proliferation of breast cancer cells; and
linked it to the cytokine secretion profile of AT-MSCs
[23]. In this study we have focused on the multiple alte-
rations induced in human Her2-positive breast cancer
cell line SKBR3 by the AT-MSCs. We have extended our
investigation also on the effect of stromal cells on drug
responses in the tumor cells. We have observed that the
AT-MSCs induced an EMT, decreased proliferation, in-
creased migration and other molecular changes in the
SKBR3 cells. We have shown that the AT-MSCs could
alter chemosensitivity of the tumor cells.
Methods
Cells
Human tumor cell line SKBR3 (ATCC® Number HTB-30™)
was used for the study. Tumor cells were maintained in
high-glucose (4.5 g/l) DMEM (PAA Laboratories GmbH)
containing 10% FBS (Biochrom AG), 10.000 IU/ml penicil-
lin (Biotica, Part. Lupca, Slovakia), 5 μg/ml streptomycin,
2 mM glutamine and 2.5 μg/ml amphotericin (PAA
Laboratories GmbH).
For mammosphere cultures, 4×104 EGFP-SKBR3 cells
per well were plated in non-adherent 6-well plates (Ultra-
low attachments plates, Corning, Amsterdam, NL) in
serum free DMEM/F12 medium (GIBCO-InvitrogenBRL) supplemented with 10.000 IU/ml penicillin (Bio-
tica, Part. Lupca, Slovakia), 5 μg/ml streptomycin,
2 mM glutamine, and 2.5 μg/ml amphotericin (Sigma,
St. Louis, MO), 10 ng/ml bFGF (Miltenyi Biotec),
10 ng/ml EGF (Miltenyi Biotec), 4 μg/ml heparin
(Sigma, St. Louis, MO), 2 μg/ml insulin (Sigma, St.
Louis, MO) and B27 supplement (diluted 1:100, Gibco-
Invitrogen BRL) and cultivated at 37°C in humidified
atmosphere and 5% CO2 for 5 days. Specific inhibitors
1.63 μM LY294002 (Sigma, St. Louis, MO) or 0.5 μM
SB203580 (Sigma, St. Louis, MO) were added to the
MSCs-CM mammosphere medium as indicated.
AT-MSCs were isolated and characterized by immuno-
phenotype and differentiation potential as previously de-
scribed in [34] (Additional file 1). The AT-MSCs were
expanded in low glucose (1.0 g/l) DMEM supplemented
with 10% HyClone® AdvanceSTEM™ supplement (Thermo
Scientific) and antibiotic/antimycotic mix (10.000 IU/ml
penicillin, 5 μg/ml streptomycin, 2 mM glutamine, and
2.5 μg/ml amphotericin). Different isolates were used for
the experiments (n = 4), each experiment was run at least
twice with each isolate to draw the conclusions. Cells were
maintained at 37°C in humidified atmosphere and 5%
CO2.
Cell-free AT-MSCs conditioned medium (MSCs-CM)
was collected from 80–90% confluent cultures after
24 hours of cultivation with fresh tumor cell culture
medium or mammosphere culture medium, respectively,
and filtered through 0.45 μm filters. Fresh MSCs-CM
was always used for the experiments.
EGFP expression
Stable transduction of SKBR3 to express enhanced green
fluorescent protein (EGFP) was done by retrovirus gene
transfer as described elsewhere [33]. Transgene incor-
poration and EGFP expression was confirmed by PCR,
reverse transcription coupled PCR and flow cytometric
analysis performed on BD Canto II cytometer (Becton
Dickinson, USA) equipped with FACS Diva program.
FCS Express software was used for evaluation. The iden-
tity of SKBR3 and EGFP-SKBR3 cells was further con-
firmed by sustained expression of epithelial cell adhesion
molecule (CD326, ≥98% positivity) verified by flow cyto-
metry with specific antibody anti-EpCAM-PE (Miltenyi
Biotec GmbH, Germany). Mouse IgG1-PE (Miltenyi Biotec
GmbH, Germany) was used as negative isotype control.
Analysis of morphological changes in EGFP-SKBR3
Three ×105 EGFP-SKBR3 cells were mixed with 1.5×105
DiI-stained AT-MSCs and cocultured for 5–9 days. For a
comparison, EGFP-SKBR3 cells alone were seeded and
cell morphology was analyzed by fluorescent microscopy
(Axiovert 200, Zeiss, Germany). Alternatively, quadrupli-
cates of 4×104 tumor cells were seeded in MSC-CM or
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were taken in the IncuCyte ZOOM™ Kinetic Imaging
System (Essen BioScience, UK). Cell confluence was
evaluated by IncuCyte ZOOM™ 2013A software (Essen
BioScience, UK) based on the confluence masks as
recommended by manufacturer.
Migration assay
Fifty thousand EGFP-SKBR3 per well were plated in trip-
licates in ImageLock 96-well plates (Essen BioScience,
UK) and let to adhere for 16 hrs. Confluent monolayers
were wounded with wound making tool (Essen Bio-
Science, UK), washed twice and supplemented with
MSC-CM or culture medium. As indicated, medium
was supplemented with receptor-tyrosine kinase inhibi-
tors 150 nM Pazopanib, 250 nM Sorafenib or 200 nM
Sunitinib (inhibitors kindly provided by National Cancer
Institute, Bratislava). Images were taken every two hours
for next 72 hrs in the IncuCyte ZOOM™ Kinetic Imaging
System (Essen BioScience, UK). Cell migration was
evaluated by IncuCyte ZOOM™ 2013A software (Essen
BioScience, UK) based on the relative wound density
measurements and expressed as means of three inde-
pendent experiments run in triplicates ± SD.
Gene expression analysis
EGFP-SKBR3 tumor cells were cultured with or without
MSC-CM for 6 days with everyday medium replenish-
ment. Total RNA was isolated from 5×106 EGFP-SKBR3
cultured with or without MSC-CM. Cultured cells were
collected by trypsinization, RNA isolated by NucleoSpin®
RNA II (Macherey-Nagel) and treated with RNase-free
DNase (Qiagen, Hilden, Germany). Total RNA was sub-
jected to control PCR to confirm the absence of genomic
DNA contamination. RNA was reverse transcribed with
RevertAid™ H minus First Strand cDNA Synthesis Kit
(Fermentas, Hanover, MD). 200 ng of cDNA was ampli-
fied in standard PCR performed in 20 μl 1x PCR master
mix (Fermentas, Canada) with 0.5 μl respective specific
primers (20 pmol/μl) and DNase free water (Fermentas,
Canada) in DNA Engine Dyad™ Peltier Thermal Cycler
(MJ Research, UK) with pre-set amplification profile and
horizontal electrophoresis was used for detection of
amplicons. Each reaction was run with appropriate no
template controls and negative control (RNA template
without reverse transriptase). Primer sequences were
listed in Additional file 2.
Quantitative PCR was performed in 1 × ABsolute™
QPCR SYBR® Green Mix (ABgene, Surrey, UK), 0.16 μM
primers and 200 ng of template cDNA on Bio-Rad
CFX96™ and analyzed by Bio-Rad CFX Manager soft-
ware version 1.6. Relative gene expression change was
calculated according to ΔΔCt method. GAPDH and
HPRT1 gene expression was taken as endogenousreference. Analysis was performed twice in triplicates
and data expressed as means ± SD.
Multiplex and SDF-1α secretion analysis
5×104 EGFP-SKBR3, 2.5×104 AT-MSCs alone, and 5×104
SKBR3 cells mixed with 2.5×104 AT-MSCs (ratio 2:1)
were plated in the wells of 24-well plates and cultured in
2 ml of complete culture medium for two days. Cell-free
supernatants were collected and subjected to human
Bio-Plex™ 27-plex Cytokine Assay (Bio-Rad Laboratories
Inc, Hercules, CA). Measurements were performed on
Luminex 100 System (Luminex Corporation, Austin,
TX) in duplicates with two different AT-MSCs isolates.
Results were expressed as mean pg/ml of culture
medium ± SD.
In order to confirm the SDF-1α secretion SDF1-α
Quantikine Immunoassay (R&D Systems Inc.) was used.
SDF-1α levels in cell free supernatants were determined
on xMark™ Microplate Spectrophotometer (BIO-RAD).
Cell proliferation
The effect on tumor cell proliferation was evaluated as a
relative fluorescence determined by green fluorescence
readout (Ex. 485, Em. 520) on PolarStar OPTIMA reader
(BMG Labtechnologies, Offenberg, Germany) in direct
cocultures. Quadruplicates of 1×104 EGFP-SKBR3 cells
were seeded in black-walled 96-well plates (Greiner Bio-
One Intl. AG) with increasing numbers of AT-MSCs and
cultured for 6 days. Green fluorescence was directly pro-
portional to the number of viable tumor cells within the
wells and the fluorescence value in the untreated cells
was set to 100% by default. Experiments were evaluated
as mean of quadruplicates ± SD.
In order to dissect the role of SDF-1α/CXCR4 axis in
proliferation of EGFP-SKBR3 cells in cocultures with
AT-MSCs, specific inhibitor of this signaling axis AMD
3100 (Sigma, St. Louis, MO) was used. Final concentra-
tion of 5 μg/ml AMD 3100 was added to EGFP-SKBR3
cells alone, cultured in MSC-CM or in coculture with
AT-MSCs. The effect on proliferation was evaluated as a
relative fluorescence as described above.
Relative cell viability was evaluated by CellTiter-Glo™
Luminescent Cell Viability Assay (Promega Corporation,
Madison, WI) based on the ATP quantitation representa-
tive of metabolically active cells. Quadruplicates of 6×103
SKBR3 cells per well were seeded in 96-well plates over-
night. Diluted MSCs-CM was added to the adherent tumor
cells on the next day. Relative proliferation was determined
on LUMIstar GALAXY reader (BMG Labtechnologies,
Offenburg, Germany). Values were expressed as mean rela-
tive luminescence ± SD, when luminescence of control cells
was taken as reference. Experiments were repeated at least
twice with similar results and a representative result is
shown.
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Following drugs were used: 5-fluorouracil (5FU, Sigma, St.
Lois, MO), doxorubicin (DOX, EBEWE Pharma, Austria)
and cis-platin (EBEWE Pharma, Austria). For the evalu-
ation of chemosensitivity, either 6×103 EGFP-SKBR3 cells
alone or mixed with AT-MSCs (ratio 2:1) were seeded in
96-well plates. On day 0, treatments were started with
doxorubicin (6.25 -100 ng/ml), 5FU (6.25-1000 ng/ml) or
cis-platin (0.001-10 μg/ml). The chemosensitivity was
determined by fluorescence measurements as described
above 6 days later. Experiments were evaluated as means
of three different experiments run in quadruplicates and
the relative fluorescence in untreated cells was taken as
100% by default. Alternatively, 8×103 EGFP-SKBR3 were
seeded in 96-well plates overnight and treated with the
drugs diluted in MSCs-CM. Relative fluorescence and cell
proliferation was determined as above.
Caspase-3/7 assay
Quadruplicates of 2×104 SKBR3 per well were seeded in
96-well white-walled plates (Corning Costar Life Sciences,
Amsterdam, NL) overnight. Doxorubicin (100 ng/ml) or
5FU (100 μg/ml and 500 μg/ml) diluted in MSC-CM or
culture media was added to the cells for the indicated
period of time and a Caspase-3/7 activity was determined
by the Caspase-Glo® 3/7 Assay (Promega Corporation,
Madison, WI) on LUMIstar GALAXY reader (BMG Lab-
technologies, Offenburg, Germany) at indicated timepoints.
Values were determined as mean values of RLU± SD.
Annexin V assay
In order to quantify a proportion of viable, apoptotic
and necrotic cells in cocultures, adherent AT-MSCs
were labeled with 5 μM carboxy-fluorescein diacetate,
succinimidyl ester (CFDA-SE, Molecular Probes, Eugene,
OR) in a serum-free DMEM for 15 min at 37°C.
Medium was replaced for standard culture medium to
incubate overnight. Next day, SKBR3 cells were mixed
with CFDA-SE labeled AT-MSCs in a ratio 2:1 and
plated onto 6-well plate (5×104 SKBR3, 5×104 AT-MSCs,
or 5×104 SKBR3 with 2.5×104 AT-MSCs/well) for direct
co-culture. Doxorubicin at final concentration 50 ng/ml
was added to the respective wells one day later and cells
were treated for 48 hrs. Apoptotic cells were stained with
Phycoerythrin-labeled Annexin V (eBioscience, San Diego,
CA); dead cells were detected with DAPI viability dye.
Cells were analyzed using BD CantoII cytometer (Becton
Dickinson, USA) equipped with FACSDiva program. FCS
Express software was used for the evaluation.
Statistical analysis
Studies involving comparison between the two groups
were analyzed by an unpaired Student's t-test inGraphPad Prism® software (LA Jolla, CA). The value of
p < 0.05 was considered statistically significant.
Results
AT-MSCs stimulate an EMT and mammosphere formation
in the breast cancer cells SKBR3
Previously we have described that AT-MSCs secrete a
plethora of chemokines and growth factors which might
affect the tumor cell behavior [23]. When SKBR3 cells
were maintained in MSC-CM morphological changes in
the majority of tumor cells could be observed (Figure 1A).
Very similar effect could be observed in the EGFP-SKBR
cells directly cocultured with the AT-MSCs for 6 days
(Figure 1B). Cells shifted from the epithelial-like cobble-
stone morphology to the spindle-like fibroblastoid ap-
pearance. EGFP-SKBR3 cells acquired mesenchymal-like
phenotype that resembled an epithelial-to-mesenchymal
transition with scattered colony appearance and increased
adherence. Up-regulation of the EMT-associated markers
in MSC-CM exposed EGFP-SKBR3 cells was confirmed
(Figure 1C). MSC-CM treated tumor cells exhibited sig-
nificantly higher expression of EMT regulators TWIST,
Snail1, Snail2, related genes αSMA (α-smooth muscle
actin) and fibroblast-activating protein (FAP) in compari-
son to unaffected EGFP-SKBR3 cells. The EMT process
was previously linked to contribute to increased stemness
[35] and an upregulation of Oct and Nanog was also de-
tected in MSC-CM exposed EGFP-SKBR3 (Figure 1C).
Paracrine factors secreted by AT-MSCs also substantially
supported SKBR3 mammosphere formation (Figure 1D).
We hypothesized that it was due to stimulation of signa-
ling pathways downstream of receptor-tyrosine kinases by
MSCs secretome. Indeed, the pharmacological inhibition
of phosphatidylinositol-3-kinase (PI3K) with specific in-
hibitor LY294002 (1.63 μM) or p38 mitogen-activated
protein (MAP) kinase with inhibitor SB203580 (0.5 μM)
prevented mammosphere formation in MSC-CM. The
viability of SKBR3 in MSC-CM and standard culture con-
ditions was decreased to the same extent by these inhibi-
tors (Figure 1D, right panel).
Paracrine signaling and migration of SKBR3 cells is
influenced by AT-MSCs
In order to further characterize the intercellular cross-
talk, we analyzed a cytokine secretion pattern in the
SKBR3-MSCs cocultures (Figure 2A). Detectable levels
of IL-5, IL-7, IL-10, GM-CSF, IFN-γ and MIP-1a could
be measured in the medium from the cocultured cells.
These chemokines were below detectable level in the
SKBR3 or MSC-CM medium. Moreover, IL-4, IL-9,
eotaxin, IP-10 and MCP-1 levels were synergistically in-
creased in the cocultures. Furthermore, the expression
of several other growth factors and their cognate recep-
tors was examined as these were previously implicated
Figure 1 (See legend on next page.)
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Figure 1 AT-MSCs induced epithelial–to-mesenchymal transition and increased mammosphere formation. A) SKBR3 cells were cultured in
DMEM or MSC-CM for 6 days. Phase-contrast images revealed shift from epithelial to mesenchymal-like morphology in the majority of tumor cells
(magnification 40x). B) AT-MSCs and EGFP-SKBR3 were directly cocultured for 6 days. Fluorescence microscopy confirmed morphological signs of
an EMT in the tumor cells (magnification 100x). C) Markers of the EMT and pluripotency were up-regulated in the tumor cells cultured in MSC-
CM. Quantitative RT-PCR confirmed significant increase in the expression of Nanog, Oct, Twist, Snail1, Snail2, αSMA and FAP in EGFP-SKBR3 cells
exposed to MSC-CM in comparison to EGFP-SKBR maintained under the standard culture conditions. The data are expressed as means ± SD,
*p < 0.05, #p < 0.001. D) Non-adherent culture conditions increased EGFP-SKBR3 mammosphere formation in the presence of MSC-CM, which
could be abrogated by specific inhibitors of PI3K (1.63 μM LY294002) and p38 MAP kinases (0.5 μM SB203580) (magnification: light microscopy
40x, fluorescent microscopy 100x). Relative viability of EGFP-SKBR3 cells exposed to MSC-CM in the presence of inhibitors did not significantly
differ from the viability in DMEM as evaluated by luminescent viability assay (right panel).
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[12,28,36]. MSC-CM induced the expression of both c-
Kit (stem cell factor receptor) and VEGFR2 receptors in
MSC-CM exposed SKBR3 cells (Figure 2B). These data
suggested that the interaction of the tumor and stromal
cells resulted in altered composition of secreted mole-
cules and expression pattern of the tumor cell.
As it was previously suggested the MSC also affected
the tumor cell migration [19]. We could confirm signifi-
cantly increased migration of MSC-CM-exposed SKBR3
in a wound healing assay as well (Figure 2C). The role of
upregulated VEGFR2 or c-Kit signaling in the increased
migration of MSC-CM-exposed SKBR3 was further exa-
mined by its pharmacological inhibition with multi-
target kinase inhibitors Sunitinib (VEGFR2, PDGFRβ
and c-Kit inhibitor), Sorafenib (VEGFR-2, Raf-1 and B-
Raf inhibitor) and Pazopanib (multi-target kinase inhibi-
tor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit
and c-Fms). The migration of SKBR3 in MSC-CM was
significantly decreased with 200 nM Sunitinib; and did
not change in 150 nM Pazopanib or 250 nM Sorafenib
(Figure 2D). These data reflect the differential properties
of these inhibitors and a capability of sunitinib to revert
MSC-CM-stimulated migration of SKBR3 cells. In
accordance with these data, HGF/c-Met signaling was
excluded to contribute to increased migration because
the expression level of HGF and c-Met did not change
and a specific inhibitor of this signaling axis SU11274
did not suppress MSC-CM stimulated SKBR3 migration
(data not shown).
AT-MSCs inhibit proliferation of breast cancer cells SKBR3
Tumor cell proliferation is frequently affected by stromal
cells; and therefore we evaluated the effect of AT-MSCs
on SKBR3 proliferation. Kinetic-life cell imaging unra-
veled significantly increased relative confluence of MSC-
CM exposed EGFP-SKBR3 (Figure 3A). This was due to
the altered morphology and increased cell adhesion of
the tumor cells with mesenchymal-like appearance due
to EMT (Figure 1A-B). The proliferation of tumor cells
was substantially inhibited both in the MSC-CM supple-
mented cultures (Figure 3B-C) and the direct cocultures
with AT-MSCs (Figure 3D). MSCs-mediated anti-proliferative effect was dose dependent and observed
with each AT-MSCs isolate examined. Based on the pre-
vious reports by the group of P. Rameshwar [21,37], we
hypothesized that CXCR4/SDF-1α could be involved in
AT-MSCs mediated proliferation inhibition. We con-
firmed that the AT-MSCs and SKBR3/AT-MSC cocul-
tures secreted SDF-1α (Figure 3E). Therefore we
examined whether the pharmacological inhibition of sig-
naling by AMD3100 (a selective inhibitor of CXCR4/
SDF-1α signaling axis) would be able to abrogate anti-
proliferative effect of AT-MSCs. EGFP-SKBR3 prolifera-
tion in 5 μg/ml AMD3100 in the presence of AT-MSCs
returned back to the value of cells in direct cocultures
without inhibitor (Figure 3F) in spite of the low CXCR4
expression in SKBR3 cells [38,39]. No significant effect
of the AMD3100 was observed in the MSC-CM exposed
SKBR3 cells, indicating the role of other paracrine fac-
tors in MSC-CM mediated inhibition of tumor cell
proliferation.
SKBR3 chemosensitivity is altered in the presence of MSC-
CM or AT-MSCs
Next, we decided to analyze whether the AT-MSCs influ-
enced the chemosensitivity of EGFP-SKBR3 cells to anti-
cancer drugs such as doxorubicin (DOX), 5-fluorouracil
(5FU) and cis-platin. Initial evaluation revealed signifi-
cantly decreased relative fluorescence of EGFP-SKBR3
cells in response to 12.5 ng/ml and 25 ng/ml doxorubicin
diluted in MSC-CM (Figure 4A). Increase in the cytoto-
xicity of 25 ng/ml doxorubicin correlated to the increasing
MSC-CM concentration (Figure 4B). Soluble factors
present in MSC-CM decrased the IC50 value for doxorubi-
cin in SKBR3 cells twofold: IC50(SKBR3) = 27 ng/ml DOX
was shifted to IC50(SKBR3 in MSC-CM) = 13 ng/ml
DOX as determined by the luminescent viability assay
(Figure 4C) due to significantly increased apoptosis in
the doxorubicin treated tumor cells in the presence of
MSC-CM (Figure 4D). Same effect could be also con-
firmed in the direct SKBR3-AT-MSC cocultures treated
with 50 ng/ml doxorubicin for 48 hrs by flow cytometric
measurements (Figure 4E). Viability of doxorubicin-
treated AT-MSCs did not significantly change in coculture
(86.0% vs. 84.5%) as expected. The viability of SKBR3 cells
Figure 2 Increased migration of breast cancer cells due to the changes in a paracrine signaling and gene expression in MSC-CM-
exposed SKBR3. A) Paracrine signaling in tumor and stromal cell cocultures. AT-MSCs were directly cocultured with EGFP-SKBR3 for 2 days and
the cytokine levels were evaluated by human Bio-PlexTM 27-plex Cytokine Assay. Direct coculture of the tumor and stromal cells resulted in induc-
tion of IL-5, IL-7, IL-10, GM-CSF, IFN-γ and MIP-1a (‡). EGFP-SKBR3 or AT-MSCs alone did not produce detectable levels of these cytokines. Levels
of cytokines IL-4, IL-9, eotaxin, IP-10, MCP-1 were significantly higher in comparison to the theoretically calculated additive value of EGFP-SKBR3
and AT-MSCs alone. Values were calculated as means of two independent experiments performed in duplicates, *p < 0.05, **p < 0.01. B) Expression
analysis demonstrated the induction of VEGFR2 and c-Kit receptor expression in MSC-CM exposed EGFP-SKBR3 cells for 6 days. The expression
of EGFR1, VEGFA, SCF and c-Met was detected in EGFP-SKBR3 cells. Induced expression of VEGFR2 and c-Kit was detected in MSC-CM cultured
EGFP-SKBR3. Representative outcome is shown; the experiments were repeated at least three times with different MSCs isolates and similar
outcome. C) EGFP-SKBR3 cells exhibited increased migration in the presence of MSC-CM as evaluated by live-cell imaging in a scratch wound
assay. Confluent monolayers of EGFP-SKBR3 cells were wounded and the migration in the presence of MSC-CM or standard culture medium
was observed for 72 hrs. Quantitative evaluation of a relative wound density demonstrated the capability of the secreted soluble factors by
AT-MSCs to significantly increase the migration of tumor cells. Data are expressed as means of three independent measurements each run in
quadruplicates ± SD. D) Increased migration of EGFP-SKBR3 in MSCs-CM could be significantly inhibited by 200 nM Sunitinib (VEGFR2, PDGFRβ
and c-Kit inhibitor); and not by 150 nM Pazopanib (multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms) or
250 nM Sorafenib (VEGFR-2, Raf-1 and B-Raf inhibitor).
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Figure 3 AT-MSCs and MSC-CM can inhibit the proliferation of SKBR3 breast cancer cells. A) MSC-CM-exposed EGFP-SKBR3 cells show
significantly increased relative confluence as determined by the kinetic live-cell imaging. Data were pooled from the three independent experi-
ments and expressed as means ± SD. B) Relative proliferation of the SKBR3 cells in serially diluted MSC-CM was determined by the viability
luminescence-based assay after 6 days. MSC-CM supplemented culture medium gradually decreased the cell proliferation in comparison to
the standard culture conditions. Proliferation was significantly inhibited in each MSC-CM dilution in comparison to standard culture medium
(p < 0.05). C) The inhibition of proliferation was determined for the three different AT-MSCs isolates tested as above, *p < 0.05. D) Direct coculture
of the EGFP-SKBR3 with AT-MSCs confirmed the inhibition of tumor cell proliferation based on the decrease in relative green fluorescence
corresponding to the signal from the viable tumor cells. Relative proliferation was significantly lower in comparison to the proliferation of EGFP-
SKBR3 alone when≥ 1,000 AT-MSCs were admixed to the 10,000 EGFP-SKBR3 cells (p < 0.05). E) Immunoassay confirmed the production of SDF-
1α in the AT-MSCs and cocultures of AT-MSCs and EGFP-SKBR3. F) EGFP-SKBR3 cells were cultured in the presence of AT-MSCs CM or AT-MSCs
with or without 5 μg/ml AMD3100 - specific inhibitor of SDF1α/CXCR4 signaling. Relative tumor cell viability was significantly lower in the
presence of AT-MSCs and the inhibitory effect was abrogated in the presence of the AMD3100. Each experiment was performed at least three
times in quadruplicates with similar results and one representative outcome is shown. Data were expressed as means ± SD. *p < 0.05.
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Figure 4 Increased chemosensitivity of SKBR3 in MSC-CM or AT-MSCs cocultures. A) Doxorubicin decreased relative fluorescence of the
EGFP-SKBR3 in the presence of MSC secreted factors, indicative of increased chemosensitivity of EGFP-SKBR3 cells in the MSC-CM to doxorubicin
concentrations of 12.5 ng/ml and 25 ng/ml, *p < 0.05. B) Relative viability of MSC-CM-exposed tumor cells is significantly lower in the presence of
25 ng/ml doxorubicin in comparison to doxorubicin treatment in culture medium, *p < 0.05. C) Direct comparison of the doxorubicin sensitivity
revealed shift in IC50(SKBR3) = 27 ng/ml DOX to IC50(SKBR3 in MSCs-CM) = 13 ng/ml DOX, as determined by luminescent viability assay, *p < 0.05.
D) Cytotoxic treatment with doxorubicin induced significantly higher Caspase-3/7 activation in the SKBR3/MSC-CM cultures as determined by a
Casp-3/7 luminescence assay. Each experiment was performed three times with four different MSCs isolates and one representative evaluation is
shown. Data are expressed as means ± SD, *p < 0.05. E) Flow cytometric analysis of the directly cocultured cells unraveled significantly increased
proportion of apoptotic and necrotic tumor cells as determined by the Annexin V and/or DAPI positivity in cocultures. Tumor cells were mixed
with AT-MSCs (2:1) and treated with 50 ng/ml doxorubicin for 48 hrs. Representative data derived from one experiment were shown, *p < 0.05.
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in the presence of AT-MSCs. Furthermore, the treatment
of EGFP-SKBR3 cells with 6.25 ng/ml, 12.5 ng/ml or
25 ng/ml 5FU in the presence of AT-MSCs significantly
increased cytotoxicity as measured by the viability assay
(Figure 5A). IC50 shifted from IC50(SKBR3) = 70 ng/ml5FU to IC50(SKBR3 in MSCs-CM) = 35 ng/ml 5FU in the
direct cocultures. 100 μg/ml and 500 μg/ml 5FU induced
significantly higher Caspase-3/7 activation in SKBR3 cells
in the presence of MSCs (Figure 5B). These 5FU concen-
trations did not induce any cytotoxicity or significantly in-
creased Caspase3/7 activity in AT-MSCs as published
Figure 5 AT-MSCs affect chemoresistance to 5FU in the direct
cocultures with SKBR3 cells. A) AT-MSCs were directly cocultured
with EGFP-SKBR3 in the presence or absence of 6.25 ng/ml - 1 μg/ml
5FU for 6 days. Relative viability of EGFP-SKBR3 was determined by
fluorescence measurements. The presence of the AT-MSCs did not
interfere with the fluorescence signal. AT-MSCs significantly decreased
the resistance to 12.5 ng/ml and 50 ng/ml 5FU. IC50 shifted from IC50
(SKBR3) = 70 ng/ml 5FU to IC50(SKBR3 in MSCs-CM) = 35 ng/ml 5FU,
*p < 0.05. B) AT-MSCs significantly increased Caspase3/7 activation in
SKBR3 cells in response to 5FU treatment for 48 hrs. No Caspase 3/7
activity was induced in AT-MSCs cell under these conditions due to
their inherent chemoresistant nature, *p < 0.05. C) AT-MSCs did not
significantly affect sensitivity of tumor cells to cis-platin treatment. Data
were derived from the three independent experiments performed in
quadruplicates. Values were expressed as means ± SD, p > 0.05.
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0.001-10 μg/ml cis-platin was not significantly changed in
the presence of AT-MSCs (Figure 5C).
Discussion
MSCs represent multipotent cells valuable for regenerative
therapies including augmentation of tissue regeneration in
breast reconstruction after cancer-related surgery. Al-
though recent results suggested that AT-MSCs might im-
prove a long-term retention of the grafts, the risks of this
cellular treatment still remain unresolved specifically in
the context of a patient with cancer history [5,6]. Tumors
always encompass both malignant part and non-
malignant cells of various cell lineages with complex mu-
tual interactions between particular cell types [2,40].
MSCs can contribute to the tumor microenvironment and
play a role in mammary carcinogenesis [11]. Our data
showed that AT-MSCs did not increase the proliferation
of the HER2-overexpressing, estrogen/progesterone recep-
tor negative breast cancer cells SKBR3. However, AT-
MSCs induced an EMT in tumor cells with increased
tumor cell migration and mammosphere formation, po-
tentially leading to increased aggressiveness and meta-
static capability. MSCs derived from bone marrow were
already described to affect breast cancer cell proliferation,
migration, invasiveness, metastasis, morphology, che-
moresistance and hormone responsiveness (reviewed in
[11,41]). According to our data the MSCs can alter tumor
biology regardless of their tissue origin. Similarities in the
MSCs secretome dictate the nature of the interaction with
the other cell types [9]. It has been shown that a gene ex-
pression profile of the MSCs derived from breast adipose
tissue is comparable to the MSCs originating from ab-
dominal adipose tissue resulting in comparable stimula-
tion of proliferation in breast cancer cells MCF7 and
MDA-MB-231 [42]. Moreover, the MSCs from primary
breast cancer tissues were also shown to exert stimulatory
effect on MCF7 proliferation and tumor growth [43]. De-
tailed study of migration properties of the tumor-cell ex-
posed MSCs have unraveled increased migration of the
MSCs isolated from breast adipose tissues in comparison
to the migration of the MSCs derived from abdominal adi-
pose tissue [44]. Gene expression profile of these migra-
tory MSCs was close to the profile of MSCs isolated from
the tumor-adjacent breast adipose tissues [44]. Thus the
MSCs derived from abdominal adipose tissue with lower
responsiveness to tumor-induced motility might be pre-
ferred exogenous cell source for fat grafting and breast aug-
mentation to limit the effect on mammary carcinogenesis.
MSCs-secreted cytokines induced an EMT, increased
expression of pluripotency genes and mammosphere for-
mation in breast cancer cells (Figure 1C-D and [24])
which might suggest the capability of MSCs to increase
the proportion of tumor initiating cells as a consequence
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VEGFR2 concomitant with high VEGFA expression in
SKBR3 cells could generate autocrine loop directly
affecting a tumor cell survival and potentially more inva-
sive phenotype [46]. Based on these data, we hypothe-
sized that SKBR3 cells in combination with AT-MSCs
might have increased tumorigenicity. However, no in-
crease in the tumor-forming capabilities was observed
when AT-MSCs were coinjected with EGFP-SKBR3 cells
in vivo. AT-MSCs could not support the xenotransplant
growth in immunodeficient mice (data not shown). The
EMT and upregulation of pluripotency genes induced by
MSC-CM was not sufficient to promote tumor growth
in low tumorigenic SKBR3 cells. Recently Karnoub's
group demonstrated that the MSCs-mediated EMT was
neither sufficient nor necessary for a generation of can-
cer stem cell phenotype, although it contributed to the
increased metastasis in vivo [47]. Future studies will be
focused on the attempt to develop tumor xenotransplant
model to test the MSCs-mediated alterations in the
tumor behavior and its chemosensitivity in vivo.
Our data further support the dual role of MSCs in
tumor cell proliferation. Previously we have reported
increased proliferation of breast cancer cells T47D,
MCF7 and MDA-MB-361 in response to AT-MSCs
[19,23] in contrast to antiproliferative action on SKBR3
cells (Figure 3). Our data correspond with the findings
by Donnenberg et al., who did not show the capability
of the AT-MSCs to increase the proliferation of dor-
mant tumor cells [6]. Several studies reported that the
MSCs could actually inhibit tumor growth in vivo
[29,48-50] although in different tumor types (glioblas-
toma, leukemic, thyroid and colon cancer cells). More
importantly, substantially altered composition of the
chemokine secretome in tumor-stromal coculture indi-
cated how an inflammatory component of the tumor
might arise in vivo [51,52]. IP-10 (chemokine CXCL10)
is an important mediator in bidirectional MSCs/breast
cancer signaling [53]. Its increase in the normoxic con-
ditions and different AT-MSCs/SKBR3 coculture model
further extends its importance in stromal/breast cancer
interactions.
MSCs were also suggested to contribute to altered
tumor drug resistance [21,22,54,55]. Recently the study by
Roodhart et al. demonstrated that cis-platin-preexposed
MSCs mediated systemic resistance to cis-platin in tumor
models including breast cancer cells MDA-MB-231 [22].
However our experiments indicated that soluble factors
present in the MSC-CM or the AT-MSCs concomi-
tantly exposed to chemotherapeutic drug in direct co-
culture were not able to mediate chemoresistance
(Figures 4 and 5). SKBR3 tumor cells in the presence of
AT-MSCs had significantly increased sensitivity to che-
motherapeutic drugs doxorubicin and 5FU that arefrequently used for the breast cancer treatment. No sig-
nificant difference in sensitivity to cis-platin (Figure 5C)
or paclitaxel (data not shown) was detected when the AT-
MSCs and tumor cells were exposed to the drug in cocul-
tures. We believe that a concomitant exposure of stromal
and tumor cells to the drug might actually increase the
treatment efficiency. Contrastingly the exposure of (circu-
lating) MSCs to the chemotherapy might induce secretion
of mediators which subsequently contributed to increased
tumor cell resistance [22,55]. It remains to be further eva-
luated, which mechanisms are drug-specific, tumor cell
type-specific or context specific. Taken together the mu-
tual tumor/stromal interactions do not only determine the
biological behavior of tumor as a complex organ, but also
its response to the chemotherapeutic treatment. The
effects of MSCs on tumor cells are multiple and depend
on the state of the tumor cell (dormant vs. actively-
proliferating), the properties of specific MSCs populations,
and interactions with other cell types, such as tumor infil-
trating immune cells origin [56]. It is important to focus
on the evaluation of interactions of MSCs with primary
tumor cells to shed more light into the operating interac-
tions and signaling pathways.
Conclusions
The aim of our study was to analyze biological effects of
AT-MSCs on breast cancer cells SKBR3. We have demon-
strated that AT-MSCs induced morphological changes,
epithelial-to-mesenchymal transition, increased adherence,
mammosphere formation, migration and decreased pro-
liferation in SKBR3. These features and mechanisms of bi-
directional signaling are shared by the MSCs originating
from adipose tissue with the bone-marrow derived MSCs
and considered to play an important role in the breast
cancer pathogenesis. Our results indicated the capability
of AT-MSCs and secreted soluble factors to increase the
chemosensitivity of SKBR3 cells to doxorubicin and 5-
fluorouracil. We concluded that the MSC-mediated influ-
ence on the drug resistance is dependent on the context of
treatment, its timing and a cell type. Based on our obser-
vations, we concluded that the tumor and stromal cells
interacted in a complex fashion that altered the properties
of tumor cells and created dynamic interaction relevant
for the tumor behavior and responses.
Additional files
Additional file 1: Figure S1. A) AT-MSCs immunophenotype was
evaluated by MSC immunophenotyping kit (Miltenyi Biotec, Cologne,
Germany). The AT-MSCs were consistently and stably positive for the
CD73, CD90 and CD105 (>90%). B) Differentiation capabilities of the
AT-MSCs were examined by previously established protocols. Adipogenic
differentiation was preformed in differentiation media composed of
αMEM medium supplemented with 15% FBS, 0.5 μM hydrocortisone,
0.5 mM isobutylmethylxanthine, and 60 μM indomethacin for 28 days.
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http://www.biomedcentral.com/1471-2407/13/535Cells were washed with PBS, fixed in 4% formalin for 1 hr, and stained for
15 min with fresh Oil Red O solution (Fisher Scientific, Hampton, NH).
Osteogenic differentiation was performed in osteogenic medium using
Osteogenic stem cell kit (StemCell Technologies, Grenoble, France) as rec-
ommended by manufacturer. Medium αMEM was supplemented with
15% human osteogenic stimulatory supplements, 10-8 M dexamethasone,
0.2 mM ascorbic acid, 10 mM β-glycerolphosphate. Medium was replaced
every 3–4 days for 28 days. Cultures were washed with PBS, fixed in 4%
formalin for 1 hr, and stained for 10 min with 1 ml of 40 mM Alizarin red
(pH 4.3). Osteogenic differentiation was confirmed by detection of red
stained calcium deposits. Chondrogenic differentiation was performed by
manufacturer’s protocol using human StemMACS ChondroDiff Media
(Miltenyi Biotec, Cologne, Germany) and toluidine blue staining. Trilineage
differentiation capacity of the AT-MSCs was confirmed.
Additional file 2: Table S1. Primer sequences.Abbreviations
5FU: 5-fluorouracil; αSMA: α-smooth muscle actin; AT-MSCs: Adipose tissue-
derived mesenchymal stromal cells; CCL5: Chemokine (C-C motif) ligand 5,
RANTES; c-Kit: Stem cell factor receptor; c-MET: Hepatocyte growth factor
receptor; CXCR4: Chemokine (C-X-C) motif receptor 4, CXCL12 receptor;
DOX: Doxorubicin; EGF: Epidermal growth factor; EGFP: Enhanced green
fluorescent protein; EGFR: EGF receptor; EMT: Epithelial-to-mesenchymal
transition; FAP: Fibroblast activating protein; FGF: Fibroblast growth factor;
GAPDH: Glyceradehyde-3-phosphate dehydrogenase; G-CSF: Granulocyte-
colony stimulating factor; GM-CSF: Granulocyte monocyte-colony stimulating
factor; HGF: Hepatocyte growth factor; HPRT1: Hypoxanthine
phosphoribosyltransferase 1; IFNg: Interferon γ; IL: Interleukin; IP-10
(CXCL10): Chemokine (C-X-C motif) ligand 10; MAP: Mitogen-activated
protein; MCP-1 (CCL2): Monocyte chemoattractant protein-1, chemokine
CCL2; MIP-1a (CCL3): Macrophage inflammatory protein-1alpha; MSC-
CM: Mesenchymal stromal cell-conditioned medium; MSCs: Mesenchymal
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